This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
More generic drug prices decreased than increased in January, a new report from ...
The FDA on Thursday approved Neurotech Pharmaceuticals’ cell therapy for an eye ...
Bayer is asking shareholders to authorize a potential equity offer that would al...
Bluebird bio went from a high-flying $10 billion company in 2018 during the heyd...
President Donald Trump's nominees for NIH director and FDA commissioner sailed t...
When some former MyoKardia execs reunited with $300 million for a new "heart hea...
Nimbus Therapeutics is getting a new CEO after more than six years, as Jeb Keipe...
Plus, news about Atea Pharmaceuticals: CytomX, Amgen stop work on T cell eng...
Roche announced a new research hub on Friday in partnership with Harvard that it...
John McHutchison started Monday as CEO and chairman of Tune Therapeutics, after ...
Johnson & Johnson scrapped its Phase 3 program for aticaprant, an experimental a...
Walgreens is entering a new chapter as it agrees to sell itself to a private equ...
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over...
It’s only been about two years since healthcare really started adopting generati...
Plus, news about Tris Pharma and ARS Pharmaceuticals: Merck KGaA’s lupus dru...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...